Targeted chemotherapy overcomes drug resistance in melanoma

Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B

(2018) Agnieszka Krzyzosiak et al.   CELL

Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs

(2017) Jingyin Yue et al.   GENES & DEVELOPMENT

The importance of FLT3 mutational analysis in acute myeloid leukemia

(2017) Mrinal M. Patnaik   LEUKEMIA & LYMPHOMA

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

(2017) Xiangjun Kong et al.   NATURE

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis

(2017) Xiaolei Gao et al.   OncoTargets and Therapy

Survival of pancreatic cancer cells lacking KRAS function

(2017) Mandar Deepak Muzumdar et al.   Nature Communications

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

(2016) Bjoern Titz et al.   Cell Discovery

Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?

(2015) A. C. Yeh et al.   CANCER RESEARCH

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

ZINC 15 – Ligand Discovery for Everyone

(2015) Teague Sterling et al.   Journal of Chemical Information and Modeling

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

(2015) Helen Gharwan et al.   Nature Reviews Clinical Oncology

PLIP: fully automated protein–ligand interaction profiler

(2015) Sebastian Salentin et al.   NUCLEIC ACIDS RESEARCH

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

(2014) K. Kemper et al.   CANCER RESEARCH

Novel copper(II) complexes as new promising antitumour agents. A crystal structure of [Cu(1,10-phenanthroline-5,6-dione) 2 (OH 2 )(OClO 3 )](ClO 4 )

(2014) Tiziana Pivetta et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

Phosphatases in the cellular response to DNA damage

(2010) Alyson K Freeman et al.   Cell Communication and Signaling

Fpocket: An open source platform for ligand pocket detection

(2009) Vincent Le Guilloux et al.   BMC BIOINFORMATICS

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

(2009) Garrett M. Morris et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

(2009) Jie Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

(2007) Melissa R. Junttila et al.   FASEB JOURNAL